Under basal and stimulated conditions, normal insulin secretion oscillates with periods in the ultradian 100-150-min range. To test the hypothesis that oscillatory insulin delivery is more efficient in reducing blood glucose levels than continuous administration, nine normal young men were each studied on two occasions during a 28-h period including a period of polygraphically recorded sleep. Endogenous insulin secretion was suppressed by somatostatin, a constant intravenous glucose infusion was administered, and exogenous insulin was infused either at a constant rate or in a sinusoidal pattern with a period of 120 min. The mean glucose level over the 28-h period was 0.72+0.31 mmol/liter lower when insulin was infused in an oscillatory pattern than when the rate of infusion was constant (P < 0.05). The greater hypoglycemic effect of oscillatory versus constant infusion was particularly marked during the daytime, with the difference averaging 1.04+0.38 mmol/liter (P < 0.03). Serum insulin levels tended to be lower during oscillatory than constant infusion, although the same amount of exogenous insulin was administered under both conditions. Ultradian insulin oscillations appear to promote more efficient glucose utilization. (J. Clin. Invest. 1995Invest. . 95:1464Invest. -1471 
Introduction
Secretion in a pulsatile or oscillatory pattern rather than at a constant rate seems to be the rule in endocrine systems. The physiological significance of pulsatile hormone secretion was first demonstrated when it was shown that intermittent, rather than continuous, delivery of GnRH was essential for normal reproductive function (1) . Physiologic implications of pulsatile release with frequencies in the so-called "ultradian" range (i.e., 1-3 h) have been since demonstrated for most hormones of the hypothalamo-pituitary axis (2) .
Oscillatory activity in the ultradian range is also prominent in the temporal organization of beta-cell secretion. Ultradian oscillations in glucose concentrations and insulin secretion have been observed in man and in laboratory animals in a variety of conditions, including fasting (3, 4) , constant glucose infusion (5) (6) (7) (8) , continuous enteral nutrition (9, 10) , meal ingestion (11) (12) (13) , and oral glucose loads (14) . These oscillations are disrupted in impaired glucose tolerance ( 15 ) , abdominal obesity (16) , and non-insulin-dependent diabetes (15, 17, 18) , suggesting that they may be important for the maintenance of normal glucose homeostasis. While a number of studies (19) (20) (21) (22) have addressed the issue of the physiological significance of more rapid, lower amplitude, 10-15-min pulsations which are superimposed on the ultradian insulin oscillations, the potential role of the ultradian pattern of human insulin secretion in controlling daytime and overnight blood glucose levels has not yet been addressed.
This study was therefore designed to test the hypothesis that oscillatory insulin delivery with an ultradian periodicity is more efficient in reducing blood glucose levels than continuous administration throughout the 24-h cycle. Endogenous insulin secretion was suppressed by somatostatin, a constant intravenous glucose infusion was administered, and exogenous insulin was infused either at a constant rate or in a sinusoidal pattern with a period of 120 min. The effects of oscillatory versus constant insulin delivery on blood glucose levels were compared during wakefulness and polygraphically recorded sleep.
Methods
Subjects. Studies were performed in nine normal young men (ages 21.3±0.7 yr). All were non-obese (body mass index 23.5±0.6 kg/M2) and had normal fasting glucose (4.66±0.16 mmol/liter) and insulin (48.9±6.6 pmol/liter) levels. None had a history of endocrine or psychiatric disorder. They were all nonsmokers who were not taking any drugs. Shift workers or subjects having traveled across time zones (24) . Plasma C-peptide levels were assayed as described previously (25) . The lower limit of the assay is 20 pmol/liter, and the intra-assay coefficient of variation averaged 6%. Plasma glucagon levels were measured with a double antibody technique as previously described (26) with a lower detection limit of 15 ng/liter and an average intra-assay coefficient of variation below 6%.
Determination ofinsulin secretory rates. In each 15-min blood sampling interval, the insulin secretion rate (ISR)1 was mathematically derived from plasma C-peptide levels using a two-compartment model for C-peptide disappearance kinetics (27) . The kinetic parameters were obtained from published demographic data adjusted for sex, age, and body surface area (28 Analysis of the glucose, insulin, and ISR profiles. To quantify the long-term (e.g., diurnal) changes in glucose and insulin independently of the ultradian oscillations, a smooth best-fit curve was calculated for each individual profile using the robust, nonlinear regression procedure proposed by Cleveland (30) with a window of 6 h. This fitting procedure was applied to the 24-h glucose and insulin profiles collected after the first 4 h of the study, i.e., when levels of glucose, insulin, and C-peptide had stabilized after the transient elevation normally associated with the initiation of a glucose infusion. The nadirs and acrophases were defined, respectively, as the times of occurrence of minima and maxima in the best-fit curve. The value of a nadir (acrophase) was defined as the level of the best-fit curve at the nadir (acrophase). The amplitude of the diurnal variation was defined as 50% of the difference between the value of the acrophase and the value of the preceding nadir and was expressed in absolute concentration units or as a percentage of the 24-h mean level.
Before quantifying the ultradian oscillations, the individual glucose and insulin profiles were smoothed using a two-point moving average as in previous studies of oscillations of insulin secretion (9, 31) . This procedure consists of replacing the value observed at time t by the 1. Abbreviations used in this paper: GH, growth hormone; ISR, insulin secretion rate; REM, rapid eye movement; SPIT, sleep period time.
arithmetic mean of the values observed at time t -A and t, where A is the sampling interval, i.e., 15 min. This procedure strongly dampens all fluctuations shorter than 30 min, allowing a better visualization of slower oscillations at the expense of a modest reduction in their amplitude. It also reduces measurement error by a factor of d2. All further calculations were performed on the smoothed profiles. To characterize the short-term (e.g., ultradian) variations in glucose and insulin independently of the diurnal rhythmicity, spectral analysis was performed on each individual series using smoothed spectral estimators as described by Jenkins and Watts (32) . A Tukey window with a width of 48 data points was used. Before spectral analysis, the data were detrended by subtracting the regression curve quantifying the diurnal variation.
Pulses in glucose and insulin levels were identified using Ultra, a computer program for pulse detection, with a threshold for pulse significance of two times the intra-assay coefficient of variation (33) . This analysis was performed on the detrended profiles smoothed by the twopoint moving average so that the measurement errors were divided by /2. Peaks of glucose and insulin levels were considered significant if their respective increments and decrements exceeded 2.8% (i.e., 2 x 2% *2) and 8.5% (i.e., 2 x 6% . /2), respectively. For each significant pulse, the increment was defined as the difference between the level at the peak and the level at the preceding trough, and was expressed in absolute concentration units (i.e., absolute increment) or as a percentage of the level at the preceding trough (i.e., relative increment). Group statistics on pulse increments were based on medians, rather than means, because of the non-Gaussian nature of their distributions.
Statistical tests. All results are expressed as mean±SEM. Differences between the conditions of constant versus oscillatory insulin infusion were examined by standard paired t tests.
Results
Patterns of glucose, insulin and glucagon levels, and insulin secretion rates during constant and oscillatory insulin infusion. In both studies, after the initiation of intravenous somatostatin infusion, endogenous insulin secretion was rapidly suppressed from 85.5±8.2 to 7.8±2.5 pmol/min within 25±2 min. As is evident from the mean profiles shown in Fig. 1 , the first few hours of glucose infusion were associated with a transient marked increase in plasma glucose levels, which resulted in a modest escape of endogenous insulin secretion from somatostatin suppression which was similar under both constant and oscillatory insulin infusion. Basal plasma glucagon levels were not different before the two studies (80.9±8.2 [constant] vs 78.6±5.1 ng/liter [oscillatory] ; P = 0.65) and decreased similarly by an average of 45% during both studies (45.9±5.3 vs 41.1±3.7 ng/liter; P = 0.16). Exogenous insulin infusion acutely elevated serum insulin levels from 48.9±6.6 pmol/liter at 0800 to overall mean levels averaging 160.2±7.2 pmol/liter during constant infusion and 153.2±6.3 pmol/liter during oscillatory infusion (P = 0.05).
The upper panels of Fig. 1 illustrate the regular oscillations of serum insulin levels resulting from administration of exogenous insulin following a sinusoidal waveshape with a period of 120 min. Computer control of the infusion pump resulted in a highly reproducible profile of serum insulin and inter-individual synchronization of the oscillations. Well-defined oscillations in glucose levels followed each insulin oscillation throughout the study period. Representative serum insulin and plasma glucose profiles during the last 24 h of the study, i.e., after the transient period of equilibration, are shown for two individual subjects in Fig. 2 . These profiles exemplify the higher efficiency of oscillatory versus constant insulin administration in controlling glucose levels.
In subject 3, daytime glucose levels during the oscillatory condi- Fig. 3 . The greater hypoglycemic effect of oscillatory versus constant insulin infusion was particularly marked during the extended daytime period after the transient phase of glucose equilibration. Indeed, daytime blood glucose levels during the oscillatory condition were lower than during the constant condition in eight of the nine subjects, with the difference averaging 1.04±0.38 mmol/liter (n = 9, P < 0.03). No subject experienced any symptoms of hypoglycemia during the experiments. Oscillatory insulin infusion remained more efficient than constant administration throughout the first half of the sleep period. In the later part of the night and in the morning, the difference between the two modes of administration was no longer apparent. Remarkably, the lower daytime glucose concentrations during oscillatory insulin infusion were achieved in the face of levels of serum insulin and endogenous insulin secretion which tended to be lower than during constant infusion, although the same amount of exogenous insulin was administered under both conditions.
Quantitative characteristics of glucose and insulin oscillations. The quantitative characteristics of the ultradian oscillations in plasma glucose and serum insulin levels under both experimental conditions are summarized in Table I . Significant pulses in plasma glucose and serum insulin were detected even during constant glucose and insulin administration. In the absence of exogenous insulin oscillations, glucose pulses were more frequent than insulin pulses. In the oscillatory condition, the frequency and the magnitude of glucose and insulin pulses were significantly increased, and the ultradian patterns of peripheral concentrations closely matched those of the exogenous insulin infusion. The fact that the number of glucose pulses (9.8±0.5 per 24 h) was less than the number of oscillations achieved in the exogenous infusion (i.e., 12 per 24 h) reflects primarily the inability of the pulse detection program to identify oscillations with an incomplete upward or downward portion at the beginning or the end of the study period. The magnitude of the oscillations in serum insulin, as quantified by the relative pulse increment, averaged 60%, indicating that the sinusoidal waveshape of the exogenous infusion (which had an amplitude of 30% around the mean level) was transmitted without significant dampening to peripheral concentrations. In contrast, the amplitude of the entrained glucose oscillations averaged < 20%. Fig. 4 shows the mean spectra of the detrended insulin and glucose profiles under both experimental conditions. Under the condition of constant insulin and glucose infusion, spectral analysis confirmed the existence of inconsistent, low amplitude oscillations in the ultradian range (i.e., periods of 60-180 min) in seven out of nine glucose profiles (peak period: 129±9 min) and in all nine insulin profiles (peak period: 122+10 min). Lower frequency variations tended to be more prominent for glucose than for insulin. Oscillatory insulin infusion had the effect of concentrating the spectral power in a narrow range around the exogenous period, i.e., 120 min. Spectral power at 120 min was significantly higher for insulin than for glucose (P < 0.0001), indicating that the exogenous oscillation obliterated more endogenous variability for insulin than for glucose.
Diurnal variations of glucose and insulin levels. Despite the fact that the mean rates of infusion of insulin and glucose were constant throughout the study, robust diurnal variations of plasma glucose and serum insulin levels were observed in all subjects in both studies. A consistent pattern with an acrophase around midsleep and declining levels after morning awakening was identified by regression analysis. Significant nocturnal acrophases were observed in all but one subject for glucose and in all subjects for insulin. Individual examples are shown in Fig.  2 . Because of the excellent inter-individual reproducibility, this diurnal rhythmicity is clearly apparent in the mean profiles shown in Fig. 1 . These diurnal variations in glucose and insulin levels were qualitatively and quantitatively similar during both constant and oscillatory insulin infusions. Sleep onset and morning awakening were associated with robust changes in plasma glucose which were not readily apparent in the insulin profiles. In the majority of glucose profiles, well defined increases occurred immediately after sleep onset, and morning awakening was followed by a sharp decline (Figs.  1 and 2 Figure 3 . Mean (+SEM) plasma glucose, serum insulin, and ISR during the four successive periods of the study in the nine subjects receiving exogenous insulin either at a constant rate (shaded bars) or in an oscillatory pattern (solid bars): initial transient period (0800-1300), daytime period (1300-2300), sleep period (2300-0700), and post-awakening period (0700-1200).
than infusion at a constant rate in controlling plasma glucose concentration. Thus, the ultradian oscillations in glucose levels and insulin secretion which have been observed in man and in laboratory animals under a variety of experimental conditions (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) may have functional significance in terms of improved efficiency of glucose regulation for a given rate of insulin delivery. The difference in glucose levels between the two modes of infusion averaged 1 mmol/liter, a clinically meaningful value. Taken together with previous observations of alterations in ultradian variations in subjects with impaired glucose tolerance and non-insulin-dependent diabetes (15, 17, 18) , our findings suggest that the disruption of the ultradian oscillatory pattern of insulin secretion may play a role in the pathogenesis of abnormal glucose regulation and contribute to the development of insulin resistance. The more marked hypoglycemic effect observed during oscillatory insulin infusion could theoretically result from a more pronounced inhibition of hepatic glucose output, an enhanced peripheral glucose disposal, or both. In response to the glucose and insulin concentrations prevailing in the present protocol, hepatic glucose output would be expected to be totally suppressed under both constant and oscillatory insulin infusion. Secretion of glucagon, the most potent stimulator of hepatic glucose production, was partially inhibited by the continuous infusion of somatostatin, and exogenous insulin administration resulted in an almost threefold increase in serum insulin levels throughout the study period. This moderate hyperinsulinemia was associated with elevated plasma glucose levels due to the exogenous glucose infusion, a combination that has been shown to strongly potentiate the suppression of hepatic glucose production (34) . For these reasons, we believe that the greater hypoglycemic effect of oscillatory, rather than constant, insulin infusion is due to an effect on peripheral glucose utilization rather than hepatic glucose production. An earlier study performed in dogs showed the existence of ultradian glucose oscillations despite almost complete suppression of endogenous glucose production, demonstrating a causal relationship to variations in peripheral glucose uptake (6) . In a subsequent study using the hyperglycemic clamp technique, evidence that glucose oscillations enhance the efficiency and stability of glucose disposal was obtained (35) .
The complex temporal organization of human insulin secretion also includes more rapid (i.e., 10-15 min) pulsations that are superimposed on the ultradian oscillations (3, (36) (37) (38) . A number of studies have examined the possible physiological significance of the rapid insulin pulses by comparing intermittent versus continuous insulin infusion in normal and/or diabetic subjects. Matthews et al. first demonstrated ( 19) in normal subjects a significant reduction in plasma glucose concentrations 1468 Sturis, Scheen, Leproult. Polonsky, and Van Cauter Irrespective of the mode of insulin infusion, a large and highly reproducible diurnal variation in the set-point of glucose nsulin infusion regulation, with higher levels of glucose and insulin during the achieved only evening and sleep periods, was apparent despite the continuous tudies (20) (21) (22) infusion of somatostatin and glucose at a constant rate. We have nd the glucose previously observed a similar diurnal variation during prolonged he mechanism constant glucose infusion without suppression of endogenous )ns, the greater insulin secretion (7, 8) and demonstrated that it reflects the tirely due to a combined effects of circadian rhythmicity and sleep, two imuction, without portant and independent physiological modulators of glucose he two oscillaregulation (23). Glucose increases after sleep onset were found h represent an to correlate with nocturnal growth hormone (GH) secretion component of (23) . The persistence of a robust diurnal variation in glucose and insulin levels in the absence of endogenous insulin secretion and in the face of glucose and insulin infusions at constant mean rates confirms the findings of previous studies showing that reduced insulin sensitivity later in the day is a major cause of the reduction in glucose tolerance (41, 42) . Involvement of GH secretion in causing the additional hyperglycemic effect of sleep may not be excluded because the dose of somatostatin used in this study was probably insufficient to suppress nocturnal GH secretion. In this study, as well as in previous investigations (7, 8, 23) , the pattern of plasma glucose changes observed during the night was different from that described as the "dawn phenomenon" in diabetic patients (43) and, in some studies but not in others, in nondiabetic subjects (44, 45) . Indeed, we observed a late evening/early nocturnal glucose rise followed by a late nocturnal glucose fall instead of the early morning glucose increase referred to as the dawn phenomenon. An important difference between the experimental conditions used here and those under which the dawn phenomenon has been observed is that a fasting state was not established since our subjects received a constant rate of glucose infusion. Thus, the stimulation of nocturnal GH secretion, which has been implicated in the pathogenesis of the dawn phenomenon during an overnight fast (46) , did not occur in our study.
In conclusion, in normal subjects, ultradian oscillations in insulin secretion appear to promote more efficient glucose utilization, thereby increasing the hypoglycemic effect of insulin. These findings raise the possibility that disturbances in the normal ultradian pattern of insulin secretion may aggravate the insulin resistance frequently present in subjects with impaired glucose tolerance or non-insulin-dependent diabetes mellitus. The hypothesis that the restoration of an ultradian pattern of insulin oscillations in conditions of glucose intolerance may contribute to the normalization of glucose control should therefore be tested.
